Envista Holdings (NVST) has come into focus after Aristotle Small Cap Equity Fund added the dental products company as a new position, highlighting structural drivers in aging demographics and demand for restorative and aesthetic procedures.

At a share price of US$23.43, Envista has had a mixed run, with the stock down 12.57% on a 1 month share price basis and 20.39% over 3 months, yet delivering a 40.13% 1 year total shareholder return as fund interest, director equity grants and solid shareholder voting support refocus attention on the longer term story.

If you are looking beyond the dental sector for fresh ideas, this could be a good moment to check out 20 top founder-led companies

So with the stock delivering a 40.13% 1 year total return yet still trading at a discount to some valuation estimates, should you see NVST as undervalued today, or has the market already priced in its future growth potential?

Most Popular Narrative: 18.3% Undervalued

Envista's most followed valuation narrative sets a fair value of $28.69 per share, which compares to the latest close of $23.43 and points to meaningful upside in that framework.

Increasing R&D investment (up 14% year-over-year) and successful launches of digital and AI-driven products (e.g., DTX Studio Clinic with AI, DEXIS CDCTs, Spark product line) enhance Envista's ability to capitalize on growing demand for digital dentistry, supporting both future revenue growth and gross margin expansion.

Curious what kind of revenue growth, margin lift and future earnings multiple are baked into that fair value, and how buybacks fit into the story? The narrative leans on a detailed path for earnings expansion, a richer P/E than the wider medical equipment space and shrinking share count to bridge today's price to that target.

Result: Fair Value of $28.69 (UNDERVALUED)

However, the story depends on key swing factors, including pressure from China’s Volume Based Procurement and the impact of tariffs and trade barriers on margins and growth assumptions.

Another View: High P/E Puts Pressure On The Story

That 18.3% DCF-style undervaluation sits alongside a very different signal from the P/E ratio. NVST trades on 56.3x earnings, compared with a fair ratio of 29.3x, a peer average of 48.5x and a US Medical Equipment industry average of 24.5x. That is a rich multiple, so how comfortable are you with paying up for the growth and margin improvement that analysts are assuming?

Next Steps

If this mix of optimism and caution resonates with you, take a moment to review the data firsthand and pressure test the assumptions that matter most to you, then look into the 4 key rewards

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at one stock story. Use targeted screeners to surface ideas you might otherwise miss.

• Spot potential value opportunities early by scanning 48 high quality undervalued stocks that combine quality fundamentals with room for the market to catch up.
• Strengthen your downside protection by reviewing 69 resilient stocks with low risk scores that carry lower risk scores and may offer a smoother ride through volatility.
• Get ahead of the crowd by searching the screener containing 21 high quality undiscovered gems before they appear on everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.